Prestige lp cervical disc arthroplasty treatment

This study was a single-center, retrospective, case-control study and was conducted from January 2014 to January 2018 at the First Affiliated Hospital of Chongqing Medical University. The medical records of hospitalized patients diagnosed with DDD (from C-3 to C-7) who received Prestige-LP cervical disc arthroplasty treatment (Medtronic Company) in our department were used for this study. The patient inclusion criteria were: (1) patients with a preoperative clinical diagnosis of DDD from C-3 to C-7, age 18–65 years, and refractory to conservative treatment for at least 6 weeks; (2) patients who underwent Prestige-LP cervical disc arthroplasty treatment (Medtronic Company); and (3) follow-up time of more than 12 months. The exclusion criteria were: (1) patients with a previous history of cervical spine surgery and trauma; (2) cervical infection, tumor, severe osteoporosis (T-score ≤-2.5), severe hypertension, rheumatoid arthritis, ankylosing spondylitis; (3) long-term nonsteroidal anti-inflammatory drug (NSAID) use; and (4) patients with severe spondylosis or facet joint degeneration, or radiographic signs of instability.